Quarterly ResultMay 6, 2026, 04:08 PM
Niagen Bioscience Q1 Net Income +24.8% to $6.32M; Divests Segment
AI Summary
Niagen Bioscience reported a 24.8% increase in net income to $6.32 million for the first quarter of 2026, primarily driven by a $4.8 million gain from the divestment of its Analytical Reference Standards and Services operating segment. Net sales saw a modest 3.3% rise to $31.47 million, while operating income significantly declined by 67.0% to $1.58 million. The company also repurchased 489,699 common shares for $2.4 million during the quarter.
Key Highlights
- Net income increased by 24.8% to $6.32 million for Q1 2026.
- Net sales grew by 3.3% to $31.47 million in Q1 2026.
- Basic earnings per share rose to $0.08 in Q1 2026 from $0.07 in Q1 2025.
- Company divested its Analytical Reference Standards and Services segment for $6.0 million, realizing a $4.8 million gain.
- Operating income decreased by 67.0% to $1.58 million in Q1 2026.
- Repurchased 489,699 common shares for $2.4 million during Q1 2026.
- Consumer Products segment net sales increased to $22.41 million.
- Ingredients segment net sales increased to $8.56 million.